{"title":"秋水仙碱对COVID-19临床转归的影响","authors":"Emad R. Issak","doi":"10.21608/asmj.2022.270144","DOIUrl":null,"url":null,"abstract":": Background: Because of the emergence of the pandemic of SARS-Cov2 infection and the Global burden of COVID-19 on the worldwide healthcare systems, it became mandatory for all researchers to search for better preventive as well treatment strategies. Aim of the Work : The aim of the work is to study the effects of colchicine on the COVID-19 patients' clinical outcomes and the inflammatory markers during the disease. Material and Methods: This comparative, randomized controlled study has been conducted on patients confirmed to have COVID-19 attending Ain Shams Isolation hospital from Feb-2021 and May-2021. The A were randomized with 130 assigned to each group follows: The Study Group (colchicine group) (n=130): included patients who received COVID-19 treatment protocol plus colchicine according to the study protocol. The Control Group (n=130): included patients who received COVID-19 treatment protocol only without colchicine. Results : Both groups were comparable regarding age, BMI, and gender. Females constituted 58.1% & 56.0% of cases in the colchicine group & the control group, respectively. At presentation, as regards the severity, both groups are comparable (p = 0.553). In day 14, the improvement in the clinical status in the colchicine group 0.64 (0.96) is significantly (p-value = 0.002) higher than in the control group 0.28 (0.99). Conclusion : The beneficial effect of colchicine in COVID-19 cases is self-evident for both the clinical status and laboratory evaluation","PeriodicalId":7450,"journal":{"name":"Ain Shams Medical Journal","volume":"161 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"IMPACT OF COLCHICINE ON THE CLINICAL OUTCOME OF COVID-19\",\"authors\":\"Emad R. Issak\",\"doi\":\"10.21608/asmj.2022.270144\",\"DOIUrl\":null,\"url\":null,\"abstract\":\": Background: Because of the emergence of the pandemic of SARS-Cov2 infection and the Global burden of COVID-19 on the worldwide healthcare systems, it became mandatory for all researchers to search for better preventive as well treatment strategies. Aim of the Work : The aim of the work is to study the effects of colchicine on the COVID-19 patients' clinical outcomes and the inflammatory markers during the disease. Material and Methods: This comparative, randomized controlled study has been conducted on patients confirmed to have COVID-19 attending Ain Shams Isolation hospital from Feb-2021 and May-2021. The A were randomized with 130 assigned to each group follows: The Study Group (colchicine group) (n=130): included patients who received COVID-19 treatment protocol plus colchicine according to the study protocol. The Control Group (n=130): included patients who received COVID-19 treatment protocol only without colchicine. Results : Both groups were comparable regarding age, BMI, and gender. Females constituted 58.1% & 56.0% of cases in the colchicine group & the control group, respectively. At presentation, as regards the severity, both groups are comparable (p = 0.553). In day 14, the improvement in the clinical status in the colchicine group 0.64 (0.96) is significantly (p-value = 0.002) higher than in the control group 0.28 (0.99). Conclusion : The beneficial effect of colchicine in COVID-19 cases is self-evident for both the clinical status and laboratory evaluation\",\"PeriodicalId\":7450,\"journal\":{\"name\":\"Ain Shams Medical Journal\",\"volume\":\"161 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ain Shams Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21608/asmj.2022.270144\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ain Shams Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/asmj.2022.270144","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
IMPACT OF COLCHICINE ON THE CLINICAL OUTCOME OF COVID-19
: Background: Because of the emergence of the pandemic of SARS-Cov2 infection and the Global burden of COVID-19 on the worldwide healthcare systems, it became mandatory for all researchers to search for better preventive as well treatment strategies. Aim of the Work : The aim of the work is to study the effects of colchicine on the COVID-19 patients' clinical outcomes and the inflammatory markers during the disease. Material and Methods: This comparative, randomized controlled study has been conducted on patients confirmed to have COVID-19 attending Ain Shams Isolation hospital from Feb-2021 and May-2021. The A were randomized with 130 assigned to each group follows: The Study Group (colchicine group) (n=130): included patients who received COVID-19 treatment protocol plus colchicine according to the study protocol. The Control Group (n=130): included patients who received COVID-19 treatment protocol only without colchicine. Results : Both groups were comparable regarding age, BMI, and gender. Females constituted 58.1% & 56.0% of cases in the colchicine group & the control group, respectively. At presentation, as regards the severity, both groups are comparable (p = 0.553). In day 14, the improvement in the clinical status in the colchicine group 0.64 (0.96) is significantly (p-value = 0.002) higher than in the control group 0.28 (0.99). Conclusion : The beneficial effect of colchicine in COVID-19 cases is self-evident for both the clinical status and laboratory evaluation